ClinicalTrials.Veeva
Menu

Find clinical trials for Colon Cancer in Los Angeles, CA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Colorectal Cancer
Colonic Cancer
Cancer
Non-Small-Cell Lung Carcinoma
Neoplasm Metastasis
Lung Cancer
Rectal Cancer

Colon Cancer trials near Los Angeles, CA, USA:

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

(SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon...

Enrolling
Colonic Neoplasms
Neoplasms, Colon
Drug: CAPEOX
Biological: Dostarlimab

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Los Angeles, California, United States and 262 other locations

with histologically or cytologically confirmed stage IV colorectal cancer coming form three different patient populations:* Cohort 1a: 6 pat...

Active, not recruiting
Stage IV Rectal Cancer
Metastatic Colorectal Cancer
Drug: ATP128
Drug: BI 754091

Phase 1

Amal Therapeutics

Los Angeles, California, United States and 11 other locations

Status recently updated

aggressive and challenging to treat. The study will test whether GSK4418959 alone or in combination with a PD-1 inhibitor agent can decrease tumor...

Enrolling
Active, not recruiting
Endometrial Cancer
Solid Tumor
Drug: GSK4418959
Biological: PD-1 inhibitor

Phase 1, Phase 2

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Los Angeles, California, United States and 21 other locations

of ST316 administered IV in subjects with selected advanced solid tumors likely to harbor abnormalities of the WNT/β-catenin signaling pathw...

Enrolling
Colon Cancer
Metastatic Colon Cancer
Drug: Fruquintinib
Drug: FOLFIRI regimen & bevacizumab

Phase 1

Sapience Therapeutics

Los Angeles, California, United States and 10 other locations

RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of...

Enrolling
Colon Cancer
Lung Cancer
Drug: RSC-1255 Dose Expansion
Drug: RSC-1255 Dose Escalation

Phase 1

Rascal Therapeutics

Los Angeles, California, United States and 2 other locations

and pembrolizumab) given together for the treatment of colorectal cancer that:* is metastatic (spread to other parts of the body);* has the ...

Active, not recruiting
Metastatic Colorectal Cancer
Biological: Pembrolizumab
Biological: Cetuximab

Phase 2

Pfizer
Pfizer

Los Angeles, California, United States and 65 other locations

Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors....

Enrolling
Non-small Cell Lung Cancer (NSCLC)
Colorectal Cancer (CRC)
Drug: RMC-6236

Phase 1, Phase 2

Revolution Medicines
Revolution Medicines

Santa Monica, California, United States and 15 other locations

care (FOLFOX plus bevacizumab) alone and in combination with novel oncology therapies in first-line metastatic microsatellite-stable colorectal cancer...

Active, not recruiting
Metastatic Microsatellite-stable Colorectal Cancer
Drug: FOLFOX
Drug: Bevacizumab

Phase 1, Phase 2

MedImmune
MedImmune

Los Angeles, California, United States and 20 other locations

dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors, including but not limited to cholangiocarcinoma, chondrosarcoma, an...

Active, not recruiting
Any Solid Tumor
Glioma
Drug: LY3410738
Drug: Gemcitabine

Phase 1

Lilly
Lilly

Los Angeles, California, United States and 32 other locations

trial determining the efficacy of adjuvant trifluridine and tipiracil (TAS-102) in combination with irinotecan in patients with ctDNA positive colon...

Enrolling
Colorectal Cancer
Colon Adenocarcinoma
Diagnostic Test: Signatera MRD ctDNA Assay
Combination Product: Standard Treatment

Phase 1

University of California Irvine (UCI)
University of California Irvine (UCI)

Orange, California, United States

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems